Palantir (PLTR) jumps on an earnings beat and increased A.I. demand. Kevin Green and Scott Durfey dive into A.I.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the secon
Telemedicine stocks could do no wrong during the pandemic. With millions on lockdown and still in need of medical care, telemedicine stocks, like Teledoc Health (NYSE:TDOC) ranfrom about $80 to
Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Recently, weight loss and diabetes watch company DexCom Inc. NASDAQ: DXCM stock plummeted by over 44% on a surprisingly bad quarterly earnings report. Management guided lower – much lower – than a
Hims & Hers is offering customers access to compounded GLP-1 weight loss drugs. Compounded drugs are only available when there's a shortage.
Spending on healthcare and online purchases is rising even as consumer wallets remain constrained. Hims & Hers offers virtual care services and prescriptions through a simple recurring subscription pl
After a late-May bull gap on the charts, healthcare stock Hims & Hers Health Inc (NYSE:HIMS) steadily worked higher to snag a record high of $25.74 on June 18.
Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Uncovering the best game-changing stocks to buy is a true holy grail for achieving considerable financial returns while investing. Here are three standout companies ready to shift the valuation landsc
Prescription stock Hims & Hers Health (HIMS) is down 2.8% to trade at $22.45 today, and last week suffered a 10.6% drawdown. The upside is that the pullback has HIMS brushing up against a historically
Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE